![]() ![]() The White House’s purchase of more than three million doses of Novavax’s vaccine also boosts the company’s fortunes. Novavax has said in the past it plans to concentrate sales of its vaccine on developing nations that have struggled to secure supplies of Covid-19 shots. might not be the primary market for Novavax’s Covid-19 shot given most of the population is already fully inoculated. ![]() This is the first vaccine that Novavax has successfully commercialized. Many analysts and investors had doubted whether the company’s Covid-19 vaccine would ever be approved in the U.S. The FDA approval is a huge victory and vote of confidence in Novavax. However, Novavax’s protein-based vaccine could be used in people who are allergic to components of the messenger RNA vaccines offered by Pfizer and Moderna, or who are concerned about those vaccines’ newer technology. Meanwhile, competing inoculations from Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) beat Novavax to market. But Novavax has endured two years of delays and setbacks in getting FDA approval for its vaccine. Novavax’s vaccine was viewed to be one of most promising inoculations against Covid-19 - so much so that former President Donald Trump’s administration pre-ordered 110 million doses at a cost of $1.6 billion. Centers for Disease Control and Prevention (CDC). Two-thirds (67%) of the American population are already fully vaccinated against the respiratory illness, according to the U.S. Politico is reporting the FDA is set to greenlight Novavax’s two-dose Covid-19 vaccine for use in adults. While this news and the order from the federal government are positive developments, Novavax’s Covid-19 vaccine comes to market late.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |